Cellceutix to Pursue 505(b)(2) Clinical Process for Psoriasis Drug - BioMedReports (subscription)

Cellceutix to engage 505(b)(2) Clinical Process for Psoriasis Drug BioMedReports (subscription) Research of a human xenograft animal model of psoriasis conducted by Cellceutix on KM-133 measuring it against methotrexate, a usually used drug today in the treatment of disease of the skin , showed a faster reduction of lesion quality (84% versus 63%), ... Cellceutix to Pursue 505(b)(2) Clinical Process for disease of the skin Drug MarketWatch (press release) all 7 news articles » Link To Article